|
|
|
|
|
|
Sponsors and Collaborators: |
University of Chicago Genentech |
Information provided by: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00517361 |
The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.
Condition | Intervention | Phase |
Metastatic Breast Cancer |
Drug: carboplatin Drug: bevacizumab |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Breast Cancer Cancer |
ChemIDplus related topics: | Carboplatin Bevacizumab Sodium chloride |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer |
Estimated Enrollment: | 36 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |||||
University of Chicago | Recruiting | ||||
Chicago, Illinois, United States, 60637 | |||||
Contact: Ezi Okafor 773-702-3936 eokafor@bsd.uchicago.edu | |||||
Principal Investigator: Rita Nanda, MD | |||||
Oncology Specialists | Recruiting | ||||
Park Ridge, Illinois, United States, 60068 | |||||
Contact: Philip Gozun 847-410-0662 pgozun@oncmed.net | |||||
Principal Investigator: Sigrun Hallmeyer, MD |
University of Chicago |
Genentech |
Principal Investigator: | Rita Nanda, MD | University of Chicago |
Responsible Party: | University of Chicago ( Rita Nanda, MD ) |
Study ID Numbers: | UCIRB 15578A |
First Received: | August 14, 2007 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00517361 |
Health Authority: | United States: Institutional Review Board |
|
|
|